Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Breast Cancer Stage IV, HER2-low Breast ...
Phase Not Applicable
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy. The overarching aim of the HER2-Ex PET trial is to study the role of precision imaging utilizing positron emission tomography (PET) with the HER2-specific tracer \[68Ga\]Ga-ABY-025 (hereafter referred to as HER2-PET) in enhancing treatment planning for patients with metastatic HER2-expressing breast cancer Patients will be allocated based on HER2-status on PET and biopsy. Patients with HER2-expressing lesions in a fresh or archived tumour biopsy will be treated with T-DXd. The study hypothesis is that PET/CT precision imaging with a contemporary HER2-radiotracer (\[68Ga\]Ga-ABY-025) can be used and can lead to a potentially better identification of patients who benefit from T-DXd treatment, thereby achieving improved treatment responses as well as fewer side effects. This study's diagnostic approach provides a more individualized treatment strategy. Additionally, this study can potentially give us a better biological understanding of HER2-expressing mBC.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Positron emission tomografy with [68Ga]Ga-ABY-025 — Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)

Primary Outcomes

  • Therapy-predictive role of HER2-PET for the clinical benefit of treatment with T-DXd in patients with HER2-expressing mBC (9-12 weeks (first response evaluation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-03
Completion: 2032-04-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Renske Altena
Collaborators: Karolinska Institutet, Affibody
Principal Investigators:
  • Renske Altena, MD PhD (STUDY_DIRECTOR) - Karolinska Institutet
Contact Information
Study Contact:
Thuy Tran, Associate Prof, PharmD, PhD
+46812377777
thuy.tran@regionstockholm.se
Renske Altena, Associate Professor, MD PhD
renske.altena@ki.se
Oscar Wiklander, MD PhD
0728449485
oscar.wiklander@regionstockholm.se.se
Karolinska University hospital
Interventions
  • Diagnostic Test: Positron emission tomografy with [68Ga]Ga-ABY-025 — Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)
Study Locations (1 sites)
Karolinska University hospital, Solna, 17176 Sweden
Eligibility Criteria
Inclusion Criteria: * Female patients age ≥18 years. * Metastatic or locally advanced breast cancer with disease progression after ≥ 1 line of chemotherapy in the palliative setting, or with disease relapse within six months after completion of (neo-) adjuvant chemotherapy. * The patient must be able and willing to provide written consent to participate in the study. * At least one metastatic lesion ≥ 10 mm is available for biopsy o Exception can be made when a recent biopsy is available (no more than 12 months old and without exposition to HER2-targeted therapy or local radiotherapy to the specific lesion). * At least one additional metastatic index lesion ≥ 10 mm for evaluation of treatment effect (according to RECIST v1.1) * WHO performance status ≤ 2. * Expected survival \> 12 weeks. * Contraceptives: Females of child-bearing potential must agree to use adequate contraception prior to study entry, for the duration of the study treatment phase and for six months after the last dose of \[68Ga\]Ga-ABY-025. Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices (IUDs), and copper IUDs. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Women must refrain from donating eggs during this same period. Should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. If a female participant is of child-bearing potential (females are considered not of childbearing potential if they are at least one year postmenopausal and/or surgically sterile), she must have a documented negative serum Pregnancy testing prior to each administration of the IMP is obligatory. Exclusion Criteria: * Contra-indications for treatment for trastuzumab deruxtecan and inability to undergo this treatment as per local treatment routines. * A previously documented metastatic tumor biopsy that was HER2-positive (IHC 3+ and/or HER2 gene amplification). * Other manifest malignancies except for basal cell carcinoma of the skin. * Inadequate cardiac, renal, bone marrow or liver function * Patients with increased risk of complications from biopsies, i.e. increased risk of bleeding, defined as * prothrombin time test (INR value) \>1.4, platelet count \<70 (109/l), activated partial thromboplastin time (APTT) \>30s. * known bleeding disorders such as haemophilia, von Willebrand disease or platelet disorders. * any anticoagulants or antiplatelet treatment that cannot be temporarily paused
Conditions Breast Neoplasm Malignant Female
Phase PHASE2
Enrollment 152
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after vacuum assisted breast biopsy (VABB) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for highly selected patients, in whom systemic treatments have provided the maximum response.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Omission of local therapies — Omission of surgery (arm A) or radiotherapy (arm B) in those patients who have had the maximum response by neoadjuvant treatments. Maximum responders are those patients with no evidence of residual disease after neoadjuvant treatment at imaging -including mammography, US evaluation and contrast imaging procedures (MRI and/or CEM)-, confirmed by VABB on marked site of ascertained lesion. This study is open to all patients with T1-2, N0-1, M0 HER2-positive or triple negative breast cancer, treated with neoadjuvant systemic treatment, irrespective of treatments delivered.

Primary Outcomes

  • Events-free survival (EFS) for each study arm. (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-25
Completion: 2035-07-25
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 152 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Principal Investigators:
  • Massimiliano Gennaro, MD (PRINCIPAL_INVESTIGATOR) - Fondazione IRCCS Istituto Nazionale Tumori Milan
Contact Information
Study Contact:
Massimiliano Gennaro, MD
+390223903246
massimiliano.gennaro@istitutotumori.mi.it
Kiara Muca
+390223903908
kiara.muca@istitutotumori.mi.it
Massimiliano Gennaro, MD
+390223903246
massimiliano.gennaro@istitutotumori.mi.it
Fondazione IRCCS Istituto Nazionale Tumori Milano
Interventions
  • Other: Omission of local therapies — Omission of surgery (arm A) or radiotherapy (arm B) in those patients who have had the maximum response by neoadjuvant treatments. Maximum responders are those patients with no evidence of residual disease after neoadjuvant treatment at imaging -including mammography, US evaluation and contrast imaging procedures (MRI and/or CEM)-, confirmed by VABB on marked site of ascertained lesion. This study is open to all patients with T1-2, N0-1, M0 HER2-positive or triple negative breast cancer, treated with neoadjuvant systemic treatment, irrespective of treatments delivered.
Study Locations (1 sites)
Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, 20133 Italy
Eligibility Criteria
Inclusion Criteria: * Women ≥ 18y. * Initial diagnosis of unifocal HER2-positive (regardless of HR status) or Triple-negative (HR positivity lower than 10% is allowed) T1-2, N0-1, M0 breast cancer. * Treated with neoadjuvant systemic treatment according to the center recommendations. * Maximum responders and/or complete pathological response proved by surgery. * Scheduled for breast conservation. * Giving specific informed consent. Exclusion Criteria: * One of the inclusion criteria missed. * Residual ductal carcinoma in situ (DCIS) at VABB and/or surgery. * Bilateral synchronous breast cancer. * Previous malignancy within 5 years. * BRCA1-2, PALB2 or p53 proven mutation carrier (VUS are exclusion criteria as well). * Patients unable to perform regular follow up.
Conditions Breast Neoplasm Female, Benign Breast Ne...
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

In cases with breast masses, Doppler resistive index values will be calculated for the mass and surrounding healthy tissue and the opposite healthy breast tissue, and their effect on distinguishing between benign and malignant masses will be evaluated.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • A Novel Approach to the Evaluation of Breast Masses Using Doppler Ultrasonography: Percentage Changes in Resistive Index Between the Mass and Surrounding Normal Parenchyma in Benign-Malignant Differentiation (3-4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-04
Completion: 2026-05-19
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ahmet Yesildag
Principal Investigators:
  • Ahmet Yeşildağ, Prof.Dr. (STUDY_DIRECTOR) - Karamanoğlu Mehmetbey Universty
  • Ahmet Yeşildağ, Prof.Dr. (STUDY_DIRECTOR) - Karamanoğlu Mehmetbey University
Contact Information
Study Contact:
Ahmet Yeşildağ, Prof.Dr
+905057728297
ahmetysd@hotmail.com
Gökçe Merve Arman, Dr.
+905058734762
gmerveturgut@gmail.com
Ahmet Yeşildağ, Prof.Dr
+905057728297
ahmetysd@hotmail.com
Karamanoğlu Mehmetbey University, KEAH
Interventions
N/A
Study Locations (1 sites)
Karamanoğlu Mehmetbey University, KEAH, Karaman, Lütfen Seçiniz. 70200 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Those with solid breast masses * Female patients * Those with pathology results Exclusion Criteria: * Hypovascular masses * Cystic breast masses * Cases with mastitis
Conditions Metastatic Breast Cancer, Locally Advanc...
Phase PHASE1, PHASE2
Enrollment 99
Locations 22 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

A Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer. This clinical trial aims to explore the role of FWD1802 in the ER+/HER2- advanced breast cancer patient population. The primary objectives are to address the following questions: Phase I Study: Determine the Recommended Phase II Dose (RP2D) and/or Maximum Tolerated Dose (MTD) of FWD1802 in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. Phase II Study: To evaluate the efficacy of FWD1802 at the RP2D in patients with ESR1-mutated ER-positive/HER2-negative locally advanced or metastatic breast cancer, using objective response rate (ORR) as the efficacy endpoint.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: FWD1802 — Eligible subjects will receive FWD1802 treatment according to their assigned dose cohort. Dose Escalation Phase: This phase is divided into a Single-Agent Lead-in Period (C0) and a Multiple-Dosing Period (C1). During the single-agent lead-in period, subjects will receive one dose on Day 1, followed by a 6-day dosing pause. In the multiple-dosing period, subjects will be administered FWD1802 once daily. Dose Expansion Phase: Subjects will receive FWD1802 once daily. Each 4-week period constitutes one treatment cycle. Treatment will continue for up to 2 years or until one of the following events occurs (whichever comes first): disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, initiation of new anti-cancer therapy, or death. Patients who remain in the study at the end of the 2-year treatment period and continue to derive clinical benefit may, upon agreement between the investigator and the sponsor, have the option to continue treatment.

Primary Outcomes

  • Phase I Study (Approximately 2 years)
  • Phase II Study (Approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-09-12
Completion: 2028-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 99 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Forward Pharmaceuticals Co., Ltd.
Principal Investigators:
  • Jian Zhang (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Limin Yin
18520159114
yinlm@forward-pharm.com
Fanfan Li
13855137365
693671174@qq.com
The Second Hospital of Anhui Medical University
Fei Xu
13711277870
Xufei@sysucc.org.cn
Sun Yat-sen University Cancer Center
Interventions
  • Drug: FWD1802 — Eligible subjects will receive FWD1802 treatment according to their assigned dose cohort. Dose Escalation Phase: This phase is divided into a Single-Agent Lead-in Period (C0) and a Multiple-Dosing Period (C1). During the single-agent lead-in period, subjects will receive one dose on Day 1, followed by a 6-day dosing pause. In the multiple-dosing period, subjects will be administered FWD1802 once daily. Dose Expansion Phase: Subjects will receive FWD1802 once daily. Each 4-week period constitutes one treatment cycle. Treatment will continue for up to 2 years or until one of the following events occurs (whichever comes first): disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, initiation of new anti-cancer therapy, or death. Patients who remain in the study at the end of the 2-year treatment period and continue to derive clinical benefit may, upon agreement between the investigator and the sponsor, have the option to continue treatment.
Study Locations (22 sites)
The Second Hospital of Anhui Medical University, Hefei, Anhui China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong China
Huizhou First Hospital, Huizhou, Guangdong China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi China
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan China
Xinxiang Central Hospital, Xinxiang, Henan China
Henan Cancer Hospital, Zhengzhou, Henan China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan China
Hubei Cancer Hospital, Wuhan, Hubei China
The Central Hospital of Yongzhou, Yongzhou, Hunan China
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for enrollment in this clinical study: 1. Voluntarily participate in the clinical trial and sign the informed consent form. 2. Female, aged ≥18 years. 3. Able to provide blood samples for central laboratory testing of ESR1 mutation status and other biomarker assessments. Phase I Study: ESR1 mutation status will be tested retrospectively. Phase II Study: Only subjects with confirmed ESR1 mutations will be enrolled (see Appendix 5 for details). 4. Histologically or cytologically confirmed locally advanced or metastatic breast cancer that is ER-positive and HER2-negative. Criteria for ER positivity: Immunohistochemistry staining shows nuclear staining in ≥10% of tumor cells. Criteria for HER2 negativity: Immunohistochemistry staining intensity is 0 or 1+; if the intensity is 2+, it must be confirmed negative by in situ hybridization. 5. Confirmed in menopause and not caused by ovarian function suppression drugs, must meet one of the following criteria: Previous bilateral oophorectomy. Age ≥ 60 years. Age \< 60 years (subdivided into the following conditions): 1. Never received chemotherapy, ovarian function inhibitors, or SERM drugs (tamoxifen, toremifene), with amenorrhea ≥12 months, and E2 and FSH levels in the postmenopausal range. 2. Received chemotherapy resulting in chemotherapy-induced amenorrhea ≥12 months, with E2 and FSH levels in the postmenopausal range. 3. Using SERM drugs (tamoxifen, toremifene), with E2 and FSH levels in the postmenopausal range. 6. Premenopausal or perimenopausal female subjects must agree to receive and maintain treatment with ovarian function suppression (LHRH agonists) during the study treatment period (ovarian function suppression treatment must be initiated at least 14 days before the first dose of study drug). 7. Prior treatment history must meet the following requirements: 1. Disease progression during or intolerance to standard therapy, or unsuitability for standard therapy. 2. Previous adjuvant endocrine therapy for at least 2 years, with recurrence during treatment or within 1 year after completion; OR at least one line of endocrine therapy for the advanced stage, with progression after at least 6 months of maintenance therapy on any line of advanced endocrine therapy (no limit on the number of endocrine therapy lines). 3. Previous chemotherapy for the advanced stage is ≤ 2 lines. 4. Prior use of fulvestrant, with an interval of at least 6 weeks between the last dose of fulvestrant and the first dose in this study. 5. An interval of at least 6 weeks is required between the last dose of prior tamoxifen and the first dose in this study. 6. Previous treatment with CDK4/6 inhibitors is ≤ 1 line. 8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (see Appendix 1 for details). 9. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Tumor lesions that have previously received radiotherapy or other local-regional treatment can only be considered measurable lesions if disease progression is confirmed. 10. Expected survival ≥ 3 months. 11. Subjects must have adequate organ and bone marrow function at screening (no blood transfusion, human albumin administration, or use of hematopoietic growth factors within 7 days prior to screening tests), defined as follows: 1. Complete Blood Count: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L. White blood cell count (WBC) ≥ 3.0 × 10⁹/L and ≤ 15 × 10⁹/L. Platelet count (PLT) ≥ 100 × 10⁹/L. Hemoglobin (HGB) ≥ 100 g/L. 2. Liver Function: Serum total bilirubin (TBIL) ≤ 1.5 × ULN. For subjects without liver metastases: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN. For subjects with liver metastases: ALT and AST ≤ 5 × ULN. 3. Renal Function: Serum creatinine (Scr) ≤ 1.5 × ULN OR creatinine clearance (Clcr) calculated by the Cockcroft-Gault method ≥ 50 mL/min. 4. Coagulation Function: Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN (for subjects on anticoagulant therapy, values should be within the therapeutic range): 1. For patients receiving warfarin, INR must be stable between 2.0 and 3.0. 2. For patients receiving heparin, APTT should be between 1.5 and 2.5 × ULN (or returned to the value prior to starting heparin therapy). 3. For prosthetic heart valves requiring anticoagulation, a stable INR between 2.5 and 3.5 is allowed. 5. Cardiac Function: Left ventricular ejection fraction (LVEF) \> 50% as shown by echocardiography. 12. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and must be non-lactating. Women of childbearing potential must agree to use effective contraceptive methods from the time of signing the informed consent form until 6 months after the last dose of the study drug. Effective methods include double barrier methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female subjects will be considered of childbearing potential unless they are naturally postmenopausal, have undergone artificial menopause, or have undergone sterilization (e.g., hysterectomy, bilateral salpingo-oophorectomy). Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from the study: 1. Leptomeningeal metastases, carcinomatous meningitis, spinal cord compression, or symptomatic or clinically unstable central nervous system (CNS) metastases. 2. History of ongoing gastrointestinal diseases or other malabsorptive conditions that may impact the absorption of orally administered study drugs, including but not limited to: 1. Inability to swallow oral medications. 2. Requirement for intravenous nutrition. 3. Prior surgery affecting absorption, including total/partial gastrectomy. 4. Crohn's disease, ulcerative colitis. 5. Treatment for active peptic ulcer disease within 6 months prior to the first dose. 6. Malabsorption syndrome, or uncontrolled nausea, vomiting, or diarrhea. 3. Patients with symptomatic visceral metastases, or those with clinically significant and unstable pleural, peritoneal, pericardial effusions, or pulmonary lymphangitic carcinomatosis. Patients who have received intracavitary infusion therapy or drainage/paracentesis may be enrolled 14 days or more after the effusion has stabilized. Other conditions deemed by the investigator as unsuitable for endocrine therapy. 4. Prior treatments do not meet the following washout periods: 1. Use of other investigational drugs or devices within 4 weeks prior to the first dose. 2. Treatment with CDK4/6 inhibitors or mTOR inhibitors within 2 weeks, or other targeted therapies, chemotherapy, or immunotherapy within 4 weeks prior to the first dose. 3. Radiotherapy, endocrine drugs, or traditional Chinese medicines with anti-tumor indications within 2 weeks prior to the first dose (washout periods for fulvestrant and tamoxifen refer to Inclusion Criterion 7). 4. Treatment with mitomycin or nitrosoureas within 6 weeks prior to the first dose. 5. Use of drugs or herbal supplements known to be moderate/strong inhibitors or inducers of CYP3A4 within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose (see Appendix 4). 6. Use of drugs that inhibit gastric acid production within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose (see Appendix 4). 7. Use of drugs that are P-glycoprotein (P-gp) inhibitors within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose (see Appendix 4). 5. Toxicities from prior anti-tumor therapy have not recovered to Grade ≤1 (except for alopecia, and chemotherapy-induced peripheral neuropathy ≤
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, transportation, etc.). The stress reduction program is over ten weeks and includes stress reduction (e.g., progressive muscle relaxation), coping, problem solving, communication, and social support. Health related social needs will be evaluated at the beginning of the study, and referrals will be made to social work to help address those needs. The study will examine stress as reported by the patients and also use biological markers.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Medical Chart Review — Undergo medical cart review
  • Procedure: Stress Management Therapy — Receive biobehavioral stress reduction intervention
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Participant Satisfaction with the Biobehavioral Intervention (Up to 2 years)
  • Profile of Mood States for the Biobehavioral Intervention (Up to 2 years)
  • Participant Biobehavioral Intervention (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-12-14
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Principal Investigators:
  • Samilia Obeng-Gyasi, MD, MPH (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Natalie Joseph, MD
216-778-7800
MetroHealth
Samilia Obeng-Gyasi, MD, MPH
614-293-6408
samilia.obeng-gyasi@osumc.edu
Ohio State University Comprehensive Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Medical Chart Review — Undergo medical cart review
  • Procedure: Stress Management Therapy — Receive biobehavioral stress reduction intervention
  • Other: Survey Administration — Ancillary studies
Study Locations (2 sites)
MetroHealth, Cleveland, Ohio 44109 United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Age \>=18 years * Untreated newly diagnosed triple negative breast cancer * Stages I-III Exclusion Criteria: * Prisoners * Male * Identifying as American Indian, Alaska Native, Asian, Native Hawaiian or Other Pacific Islander * Individuals not able to speak and understand English * Known personal history of ductal carcinoma in situ (DCIS) or invasive breast cancer * Stage IV breast cancer
Conditions Breast Cancer, Chest Wall Tumor
Phase PHASE2
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II single center, open-label, non-randomized study in patients with locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall. Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle Forty-six patients will be required for the study. Key inclusion criteria are PDL1 (≥1%) positive and/or tumor infiltrating lymphocyte positive (≥1%) locally advanced "chest wall" breast cancer (with or without distant metastases), who have been treated with chemotherapy or radiation therapy may be eligible for this study. Patients with cutaneous metastases only (with or without evidence of primary tumor) are eligible for the study. Key exclusion criteria included prior anti PD1 or anti CTLA-4 or other immune pathway-targeted therapy. Patients with autoimmune diseases and/or receiving drugs who interfere with the immune system will not be eligible.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pembrolizumab — Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle

Primary Outcomes

  • Objective response (Participants will be followed for the duration of treatment, an expected average of 6-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-05-20
Completion: 2025-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Contact Information
Study Contact:
Giuseppe Curigliano, MD PhD
+390257489001
giuseppe.curigliano@ieo.it
Bruno Duso, MD
+390257489001
bruno.duso@ieo.it
Giuseppe Curigliano, MD
00390257489001
giuseppe.curigliano@ieo.it
Istituto Europeo di Oncologia
Interventions
  • Drug: Pembrolizumab — Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
Study Locations (1 sites)
Istituto Europeo di Oncologia, Milan, 20141 Italy
Eligibility Criteria
Inclusion Criteria: * Histologically proven, PDL1 (≥1%) positive and/or tumor infiltrating lymphocytes (TILs) positive (≥1%), locally advanced "chest wall" breast cancer (with or without distant metastases), who have been treated with chemotherapy or radiation therapy may be eligible for this study. Patients with cutaneous metastases only (with or without evidence of primary tumor) are also eligible; * Patients must have tissue accessible for serial biopsies; * Expected survival of \> 3 months; * Be willing and able to provide written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor; * Be 18 years of age on day of signing informed consent; * Be a female or male subject with IBC with lymphangitic spread to the chest wall. ER, PgR and HER2 status determination is required for enrollment; * Have provided tissue for PD-L1 biomarker analysis from a newly obtained core or excisional biopsy of a tumor lesion (mandatory) and received permission for enrollment from the Core Lab based on the adequacy of the biopsy specimen. Repeat samples may be required if adequate tissue is not provided; * Have measurable metastatic disease based on irRECIST criteria as determined by central radiology review. Tumor lesions situated in a previously irradiated area are considered measurable, if progression has been demonstrated in such lesions. Note: The exact same image acquisition and processing parameters should be used throughout the study; * Have a performance status of 0 or 1 on the ECOG Performance Scale. Assessment should be performed within 10 days of treatment initiation; * Female subjects of childbearing potential (Section 2.9.2) must be willing to use an adequate method of contraception as outlined in Section 2.9.2 - Contraception, for the course of the study through 120 days after the last dose of study medication; * Male subjects childbearing potential (Section 2.9.2) must agree to use an adequate method of contraception as outlined in Section 2.9.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject; * Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; * Patients with hormone receptor-positive and/or HER2-positive breast cancer would be eligible for the study only if their disease is considered refractory to hormonal or anti-HER2 agents, respectively, and no further hormonal or anti-HER2 treatment is indicated; * Demonstrate adequate organ function as defined in protocol, all screening labs should be performed within 10 days of treatment initiation; * Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; * Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject; * Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Exclusion Criteria: * Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; * Has a known history of active TB (Bacillus Tuberculosis); * Hypersensitivity to pembrolizumab or any of its excipients; * Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier; * Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Note 1: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note 2: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer; * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability; * Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; * Has known history of, or any evidence of active, non-infectious pneumonitis; * Has an active infection requiring systemic therapy; * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator; * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment; * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; * Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies); * Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected); * Has received a live vaccine within 30 days of planned start of study therapy. Not
Conditions Breast Cancer, Prostate Cancer, Colorect...
Phase NA
Enrollment 306
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to see if survivors of breast, prostate, colorectal or lymphoma cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Fitbit — Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
  • Behavioral: Nutrition Course: Group Sessions — The nutrition course will follow a combined asynchronous and synchronous approach. The asynchronous component will consist of a pre-recorded session covering educational nutrition content, which will be made available to participants for self-paced learning. This will be followed by a synchronous, 30-60 minute live group education class on nutrition information for cancer survivors, held once per week.
  • Behavioral: Physical Activity Program: Group Sessions — The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
  • Behavioral: Nutrition Course: One on One Sessions with Registered Dietitian — Participants will be referred to weekly one on one nutrition counseling sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
  • Behavioral: Physical Activity Program: One on One Sessions with an Exercise Physiologist — Participants will be referred to weekly one on one exercise training sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
  • Behavioral: Nutrition and Physical Activity Prescription — Participants will receive a lifestyle medicine prescription pad, developed by the investigators, which serves as a checklist to assist participants in effectively monitoring their dietary habits and physical activity routines. Participants will also receive an 8-week text messages program which will direct participants to a webpage with nutrition and physical activity content.

Primary Outcomes

  • Percentage of Survivors Who Agree to Participate (Up to 8 Weeks)
  • Percentage of Interventions Sessions Completed (Up to 8 Weeks)
  • Percentage of Participants Satisfied with the Intervention (Up to 8 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-18
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 306 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: The Applebaum Foundation
Principal Investigators:
  • Tracy Crane, PhD, RDN (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Grey Freylersythe, BS
305-243-9832
g.freylersythe@med.miami.edu
Tracy Crane, PhD, RDN
305-243-8255
tecrane@med.miami.edu
Grey Freylersythe, BS
(305) 243-9832
g.freylersythe@med.miami.edu
University of Miami
Interventions
  • Other: Fitbit — Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
  • Behavioral: Nutrition Course: Group Sessions — The nutrition course will follow a combined asynchronous and synchronous approach. The asynchronous component will consist of a pre-recorded session covering educational nutrition content, which will be made available to participants for self-paced learning. This will be followed by a synchronous, 30-60 minute live group education class on nutrition information for cancer survivors, held once per week.
  • Behavioral: Physical Activity Program: Group Sessions — The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
  • Behavioral: Nutrition Course: One on One Sessions with Registered Dietitian — Participants will be referred to weekly one on one nutrition counseling sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
  • Behavioral: Physical Activity Program: One on One Sessions with an Exercise Physiologist — Participants will be referred to weekly one on one exercise training sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
Study Locations (1 sites)
University of Miami, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria - Healthcare Providers 1. Provide full- or part-time care in an oncology clinical care setting at Sylvester Comprehensive Cancer Center 2. Utilize the electronic medical record for patient documentation on a regular basis 3. Willing to complete a 30-60-minute interview Inclusion Criteria - Patients 1. 18 years of age or older 2. Any sex/gender 3. Able to provide consent 4. Able to read/understand English or Spanish 5. Diagnosis of breast, prostate, colorectal or lymphoma cancer, 6 months post completion of primary treatment, with no evidence of primary disease 6. Approval from treating oncologist, confirmed via email or in writing 7. Fail to meet at least one of the American Cancer Society guidelines: engaging in \>150 minutes of moderate-to-vigorous physical activity per week for the prior month or consuming at least 3 cups of vegetables and 2 cups of fruit per day over the past month. 8. Internet access on a smart phone, tablet, or computer 9. Agree to be randomly assigned to any study group Exclusion Criteria: 1. Less than 18 years of age 2. Unable to provide consent 3. Unable to read/understand English or Spanish 4. Any contraindication for diet change or exercising as determined by physician 5. Blank 6. Engaging in \>150 minutes of moderate to vigorous physical activity on average per week for the prior month 7. Meeting the American Cancer Society diet recommendations (3 cups of vegetables or legumes, 2 cups of fruit, 2 serving whole grain per day, and limited red/processed meats, sugar-sweetened beverages, and highly processed foods) for the prior month 8. History of dementia or major psychiatric disease which would interfere with study participation 9. History of recent (≤1 yr) stroke, myocardial infarction or congestive heart failure 10. Eastern Cooperative Oncology Group (ECOG) score of \>2 11. Severe lymphedema as determined by physician 12. Receiving physical therapy treatment
Conditions Breast Cancer
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate the effectiveness of an intervention to promote breast cancer screening mammography among women in one community on the Navajo Nation. The intervention is Tablet-based Education to improve the Acceptance of Mammography (TEAM). TEAM encompasses culturally-tailored mammography education modules that were developed using a community-based participatory research process. Women will be randomized to receive TEAM or TEAM + Navigation. Navigation involves monthly 1:1 support from a Diné peer-navigator.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Navigation — Navigation is provision of 1:1 support from a Diné peer-navigator
  • Behavioral: TEAM — TEAM encompasses culturally tailored mammography education modules

Primary Outcomes

  • Number of participants with mammography (3 months post baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-02
Completion: 2028-03
Eligibility
Age: 40 Years – 74 Years
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins Bloomberg School of Public Health
Collaborators: Genentech Foundation
Principal Investigators:
  • Katie Nelson, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Katie Nelson, PhD
410-955-6931
knelso46@jhmi.edu
Kristen Mitchell, MS
928-674-5051
Navajo Nation Center for Indigenous Health
Interventions
  • Behavioral: Navigation — Navigation is provision of 1:1 support from a Diné peer-navigator
  • Behavioral: TEAM — TEAM encompasses culturally tailored mammography education modules
Study Locations (1 sites)
Navajo Nation Center for Indigenous Health, Chinle, Arizona 86503 United States
Eligibility Criteria
Inclusion Criteria: * Self-identify as American Indian or Alaska Native (AIAN) * Identify as Female * Are 40-74 years of age * Are a registered patient at Chinle Comprehensive HealthCare Facility (CCHFC) * Live within 80 miles of CCHFC * Have not received a mammogram within the prior 12 months * Do not have a personal history of breast cancer * Are not planning to move in the next 6 months * Willing to be randomized Exclusion Criteria: * Do not self-identify as American Indian or Alaska Native (AIAN) * Do not identify as Female * Are not 40-74 years of age * Are not a registered patient at CCHCF * Do not live within 80 miles of CCHCF * Have received a mammogram within the prior 12 months * Have a personal history of breast cancer * Are planning to move in the next 6 months * Unwilling to be randomized
Conditions Metastatic Malignant Neoplasm to Brain, ...
Phase PHASE2
Enrollment 45
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Palbociclib — Administered orally once per day on days 1-21 of 28-day cycles.
  • Drug: Pembrolizumab — Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.

Primary Outcomes

  • Intracranial Clinical Benefit Rate (Cohort 1) (8 weeks (Screening through 8 weeks))
  • Intracranial Clinical Benefit Rate (Cohort 2) (8 weeks (Screening through 8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2017-02-02
Completion: 2029-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Pfizer, Merck Sharp & Dohme LLC
Principal Investigators:
  • Nancy Wang, MD, MPH (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Nancy Wang, MD, MPH
617-724-8770
Nwang6@mgb.org
Nancy Wang, MD, MPH
617-724-8770
Nwang6@mgb.org
Massachusetts General Hospital
Nancy Wang, MD, MPH
Massachusetts General Hospital
Interventions
  • Drug: Palbociclib — Administered orally once per day on days 1-21 of 28-day cycles.
  • Drug: Pembrolizumab — Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.
Study Locations (2 sites)
Massachusetts General Hospital, Boston, Massachusetts 02115 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed disease from any solid tumor (Cohort 1) * Participants must have histologically or cytologically confirmed disease from breast cancer or melanoma (Cohort 2). * Participants must have measurable disease in the CNS, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm. * Participants must have progressive CNS lesions, as defined by one of the following: * Patients may have multiple progressive CNS lesions, some of which have been treated by SRS or surgery. Patients are eligible if they have one or more un-treated (by surgery or SRS) progressive lesions that is measurable. * Patients have measurable residual or progressive lesions after surgery. * Patients who have had prior WBRT and/or SRS are eligible but there needs to be unequivocal evidence of progression of at least one lesion treated by radiation (e.g. tissue diagnosis). Biopsy can be considered for definitive diagnosis. * Patients who have previously been treated with systemic therapy for CNS metastases are eligible. * Age \> 18 years. The toxicity of palbociclib in children is unknown. * ECOG performance status of 0, 1 or 2 (Karnofsky ≥ 60, see Appendix A). * Participants must have normal organ and marrow function as defined below: * leukocytes ≥3,000/mcL * absolute neutrophil count ≥1,500/mcL * platelets ≥100,000/mcL * hemoglobin ≥9g/dL * total bilirubin \< 1.5 x institutional upper limit of normal OR \> 1.5 x institutional upper limit of normal allowed if direct bilirubin is within normal range. * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal * creatinine within normal institutional limits OR * creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal (Cohort 1) * creatinine clearance ≥30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal (Cohort 2) * baseline QTc \<480ms * The effects of palbociclib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of palbociclib administration. * Ability to understand and the willingness to sign a written informed consent document. * Tissue from a prior biopsy or resection of intracranial or extracranial site (primary or metastatic site) for clinical genetic sequencing (at least one FFPE block or 15 unstained slides). Patients previously assessed for genetic sequencing who meet requirements of section 9.2.1 do not need to have additional tissue available for prospective genetic screening. * Presence of alteration in CDK pathway in any biopsy or resection (amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A) as described in Section 9.2 using a CLIA-certified assay (Cohort 1 only). * Patients with progressive extracranial disease will not be excluded. * Stable dose of corticosteroids for at least 7 days. * Participants who are HBsAg positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks, and have undetectable HBV viral load prior to enrollment * Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention * Hepatits B screening tests are not required unless: * Known history of HBV infection * As mandated by local health authority * Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening. * Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to enrollment * Heptatits C screening tests are not required unless: * Known history of HCV infection * As mandated by local health authority Exclusion Criteria * Prior treatment with CDK4/6 inhibitor. * Participants who have had chemotherapy, immunotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have ≥ grade 2 adverse events due to agents administered more than 2 weeks earlier. * Participants who are receiving any other investigational agents. * Participants who are receiving other concurrent chemotherapies or immunotherapies for their cancer (except for patients who will receive letrozole, anastrozole, exemestane, tamoxifen, fulvestrant, trastuzumab, bisphosphonates, or ovarian suppression therapy) * Leptomeningeal involvement of cancer (Cohort 1). Leptomeningeal involvement is allowed for Cohort 2. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib (including abemaciclib). * Participants receiving any medications or substances that are moderate or strong inhibitors or inducers of CYP3A isoenzymes are ineligible. Lists including medications and substances known or with the potential to interact with the CYP3A isoenzymes are provided in Appendix C, and can also be found within section 5.4. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because the effect of palbociclib on a developing fetus is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with palbociclib, breastfeeding should be discontinued if the mother is treated with palbociclib. If a participant inadvertently becomes pregnant while on treatment with pembrolizumab, the participant will be immediately discontinued from study intervention(s). The site will contact the participant at least monthly and document the participant's status until the pregnancy has been completed or terminated. The outcome of the pregnancy will be reported to Merck within 2 working days if the outcome is a serious adverse experience (e.g. death, abortion, congenital anomaly, or other disabling or life-threatening complication to the mother or newborn). The study Investigator will make every effort to obtain permission to follow the outcome of the pregnancy and report the condition of the fetus or newborn to Merck. If a male participant impregnates his female partner, the study personnel at the site must be informed immediately and the pregnancy must be reported to the Overall PI, Merck and Pfizer and followed as necessary. * HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with palbociclib. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving co
Conditions Breast Cancer Patients
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study, delivered by Portsmouth Hospitals University NHS Trust in conjunction with the Research Group in Breast Health at the University of Portsmouth \[1\], aims to assess whether it is possible to test breast biomechanics in women who have had surgery with or without radiotherapy for the treatment of breast cancer.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • To determine the feasibility of recruitment to a breast biomechanics study in women treated for early breast cancer with surgery +/- adjuvant radiotherapy. (From enrollment to the end of study [through study completion, an average of 1 year])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-06
Completion: 2027-01-28
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Portsmouth Hospitals NHS Trust
Collaborators: University of Portsmouth
Principal Investigators:
  • Edward St John (PRINCIPAL_INVESTIGATOR) - Portsmouth Hospitals NHS Trust
Contact Information
Study Contact:
Amy Huseyin
02392 286000
Amyrose.Huseyin@porthosp.nhs.uk
Interventions
N/A
Study Locations (1 sites)
Queen Alexandra Hospital, Portsmouth, PO6 3LY United Kingdom
Eligibility Criteria
Inclusion Criteria: * Female * 18 years of age or above * Early or locally advanced breast cancer classified as B5a or B5b (radical treatment intent) * Unilateral breast cancer (contralateral breast used as control) * Receiving or has received breast cancer surgery * +/- Adjuvant radiotherapy * Able to travel to the University of Portsmouth Breast biomechanics laboratory * Participant has capacity to consent. Exclusion Criteria: * Metastatic breast cancer diagnosis * \< 2 weeks post-operative * \< 4 weeks post-radiotherapy * Active post-operative breast infection * Requirement of ongoing breast dressings * Previous breast surgery to contralateral breast * Bilateral breast cancer * Epilepsy (due to strobe on 3D scanner) * Pregnancy or \<6 weeks post-partum * Breastfeeding * Rockwood Frailty score \>5 (or those unable to ambulate un-aided) * Requiring interpreter.
Conditions Breast Cancer
Phase NA
Enrollment 71
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study is a single-center, open-label, prospective, clinical cohort study. It enrolled patients in three subgroups: triple negative, HR+HER2-, or HR-HER2+ subtypes, who will receive neoadjuvant treatment according to guidelines. Patients in each subgroup will be divided into two categories: those responsive to neoadjuvant therapy and those resistant to it, based on the efficacy of the treatment. Tumor tissue samples from all enrolled patients before and after neoadjuvant therapy will be collected. We will explore transcriptomic differences in neoadjuvant therapy responders or resisters under the same treatment regimen, as well as transcriptomic changes in tumor tissue before and after treatment, based on single-cell sequencing and spatial transcriptomic technology.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Single-cell sequencing and spatial transcriptome — Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.

Primary Outcomes

  • RECIST1.1 Evaluates clinical efficacy (At 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2027-04-30
Eligibility
Age: 25 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 71 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital
Contact Information
Study Contact:
Ju liang J L Zhang
029-84775271
vascularzhang@163.com
Ju liang J L Zhang
029-84775271
vascularzhang@163.com
Xijing hospital
Interventions
  • Diagnostic Test: Single-cell sequencing and spatial transcriptome — Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.
Study Locations (1 sites)
Xijing hospital, Xi'an, Shaanxi 710032 China
Eligibility Criteria
Inclusion criteria: 1. Voluntary enrollment, able to understand and sign the informed consent form; 2. Female, aged 25 to 70; 3. Meet the indications for neoadjuvant therapy (based on the indicated population clearly defined in the 2023 CSCO Breast Cancer Diagnosis and Treatment Guidelines); 4. No previous systemic treatment for breast cancer; 5. The neoadjuvant treatment regimen met the inclusion requirements: triple-negative breast cancer (T-EC+antiPD-1/T-EC/antiPD-1) HER2+ HR-breast cancer (EC-THP/HP), HER2-HR+ breast cancer (AI/AI+CDK4/6i); 6. Tumor specimens can be obtained (including puncture, minimally invasive, incision biopsy, and surgery); 7. A complete pathological report can be obtained. Exclusion Criteria: 1. The patient did not sign the informed consent form; 2. Tumor specimens cannot be obtained (including puncture, minimally invasive, incision biopsy, and surgery); 3. Patients with severe systemic infections or accompanied by other serious diseases; 4. Have received cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any previous reason; 5. Does not meet the indications for neoadjuvant therapy; 6. Neoadjuvant treatment regimens are not included in the neoadjuvant treatment regimens defined in this study; 7. Other circumstances where the researcher deems it unsuitable for inclusion. Criteria for Subjects to withdraw from the study (1) All subjects can voluntarily withdraw at any stage of the study without being discriminated against or retaliated against, and their medical treatment will not be affected. (2) Furthermore, the subjects may withdraw from this study under the following circumstances: 1. Withdrawal decided by the researcher: A: The patient does not meet the indications for the above-mentioned designated neoadjuvant regimen; B: In cases where the subjects are not suitable to continue the trial during the research process, such as when the patients cannot tolerate immunotherapy or chemotherapy, the established neoadjuvant treatment plan needs to be terminated; C: Those who accept the neoadjuvant treatment regimen specified in this study and show disease progression in the cycle evaluation need to terminate the neoadjuvant treatment in advance and undergo surgical resection of the tumor tissue. D: Adverse events occurred. It was judged by the researchers that continuing to participate in the study would have an adverse impact on the safety of the subjects. E: Subjects with poor compliance, which affects the assessment of tolerance; F: The researcher requests the subjects to withdraw from the study for any medical reason; G: The researchers believe that the subjects have other circumstances that make them unsuitable to continue participating in the trial. 2. Voluntary withdrawal of the subjects: A: The subject was unwilling to continue participating in the study and voluntarily withdrew the informed consent form. B: Loss to follow-up (Before loss to follow-up, subjects who have completed three visits should be attempted to be contacted).
Conditions Breast Cancer, Invasive Breast Cancer, C...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Tissue will be procured during a standard of care procedure the patient will already be scheduled to undergo. A one time blood draw will be performed at this time and an optional rectal swab for biome analysis may occur. Follow Up will only consist of chart review to determine date of recurrence, metastases, and/or death

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Tissue Sample collection — Tissue sample collected following standard of care procedure patient was already scheduled to have
  • Other: Blood Sample Collection — A one time sample of blood will be collected on day of standard of care procedure
  • Other: Rectal Swab — optional rectal swab may be collected on day of standard of care procedure

Primary Outcomes

  • Tumor biomarker identification (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-05-10
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thomas Jefferson University
Principal Investigators:
  • Nicole Simone, MD (PRINCIPAL_INVESTIGATOR) - Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Contact Information
Study Contact:
Nicole Simone, MD
215-955-6702
Nicole.Simone@jefferson.edu
Nicole Simone
2159556702
Nicole.Simone@jefferson.edu
Sidney Kimmel Cancer Center at Thomas Jefferson University
Interventions
  • Procedure: Tissue Sample collection — Tissue sample collected following standard of care procedure patient was already scheduled to have
  • Other: Blood Sample Collection — A one time sample of blood will be collected on day of standard of care procedure
  • Other: Rectal Swab — optional rectal swab may be collected on day of standard of care procedure
Study Locations (1 sites)
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * Adults \>18 years old at time of consent * Subject must be capable to giving informed consent or have an acceptable surrogate capable of giving consent on the subject behalf. * Patients with carcinoma in situ or invasive breast cancer * Patient must be undergoing one of the following: * definitive surgical tumor resection for breast cancer OR * placement of a vascular access device as a prelude to neoadjuvant therapy for breast cancer OR * neurosurgical resection of a brain metastasis from primary breast cancer. Exclusion Criteria: * \<18 years old * Not able to give informed consent and does not have acceptable surrogate capable to giving informed consent. * Active drug/alcohol dependence or abuse history